In vitro models of a three-drug regimen (epirubicin, cisplatin and fluorouracil) for the treatment of colorectal cancer
| Autor: | Elisabetta Caliò, Patrizia Seminara, Gargano L, Teresa Aronne, Enrico Sbaffi, Fabrizio Franchi, V. Pagani Guazzugli Bonaiuti |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2001 |
| Předmět: |
Pathology
medicine.medical_specialty Combination therapy Colorectal cancer 5-fluorouracil cisplatin colorectal cancer epirubicin three-drug regimen Sulforhodamine B Cell Count Adenocarcinoma chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols Drug Discovery Tumor Cells Cultured medicine Humans Drug Interactions Pharmacology (medical) ECF Regimen Cytotoxicity Epirubicin Fluorescent Dyes Pharmacology Cisplatin Rhodamines business.industry General Medicine medicine.disease Infectious Diseases Oncology chemistry Drug Resistance Neoplasm Fluorouracil Colonic Neoplasms Cancer research business medicine.drug |
| Popis: | The activity of epirubicin, cisplatin and 5-fluorouracil (5-FU), as single agents or in combination (ECF), was investigated in three human colon cancer cell lines by two different assays (cell-counting assay and sulforhodamine B assay) in vitro. 5-FU was tested with both short and continuous exposure. Particular interest was focused on the results obtained in the HCT8-FU cell line, a subline with experimentally induced resistance to 5-FU. The positive modulation of both cisplatin and epirubicin cytotoxicity by 5-FU makes the ECF regimen an attractive protocol for combination therapy in colorectal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|